Effects of tropicamide on catalepsy and motor function in a mouse model of Parkinson’s disease
Open Access
- 11 June 2025
- journal article
- Published by Wolters Kluwer Health in Aging Advances
- Vol. 2 (3) , 89-93
Abstract
JOURNAL/agad/04.03/02274129-202509000-00001/figure1/v/2026-04-22T110229Z/r/image-tiff Parkinson’s disease is a progressive disorder characterized by dopaminergic neuronal apoptosis in the basal ganglia. The prevalence of this condition increases with age. A key deficit in Parkinson’s disease is the loss of automaticity, which affects the patients’ daily activities. Levodopa is the most effective treatment for Parkinson’s disease. However, because it is not effective for all patients in later stages of the disease, new approaches have been proposed. This study investigated the effects of tropicamide, an M4 muscarinic receptor antagonist, on catalepsy and gait in an animal model of Parkinson’s disease. Two experiments were conducted. In both experiments, animals were injected with either haloperidol to induce Parkinson’s disease-like symptoms or saline as a placebo for the control group. In Experiment I, animals received an intraperitoneal injection of either tropicamide (the experimental intervention) or saline (the placebo). In Experiment II, tropicamide or saline was administered intracerebrally instead of intraperitoneally. Catalepsy was assessed using the Bar Test and gait was evaluated using the open field test. Haloperidol induced catalepsy and motor impairments resembling those observed in Parkinson’s disease. Tropicamide administration, both intraperitoneally and intracerebrally, reversed haloperidol-induced deficits. These findings suggest that tropicamide can potentially mitigate Parkinson’s disease-related motor impairment. They also suggest a strong interaction between the M4 muscarinic receptors and dopaminergic pathways in the basal ganglia. These results underscore the importance of developing new pharmacological strategies targeting M4 muscarinic receptors in patients with Parkinson’s disease.Keywords
This publication has 47 references indexed in Scilit:
- Co‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With HaloperidolNeuropsychopharmacology Reports, 2025
- Inflammation as common link to progressive neurological diseasesArchives of Toxicology, 2023
- Oleanolic acid alleviates the extrapyramidal symptoms and cognitive impairment induced by haloperidol through the striatal PKA signaling pathway in miceBiomedicine & Pharmacotherapy, 2023
- Initiation and progression of α-synuclein pathology in Parkinson’s diseaseCellular and Molecular Life Sciences, 2022
- Interactions of a boron-containing levodopa derivative on D2 dopamine receptor and its effects in a Parkinson disease modelJBIC Journal of Biological Inorganic Chemistry, 2021
- Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disordersMovement Disorders, 2019
- Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical ManagementNeurology and Therapy, 2018
- Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s DiseaseCNS Drugs, 2017
- The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptorsPsychopharmacology, 2007
- AChE-stained horizontal sections of the rat brain in stereotaxic coordinatesJournal of Neuroscience Methods, 1980